Gandolf3,
Good to hear from you and thanks for your thoughtful query!
Ha ha! I'm looking down on him and you're looking up at him.
If we don't hear from DNAP this week to explain the BioF transaction not closing, then I will join any clamoring for it.
The pps is where it is because of La Jolla financing which was apparently the best they could get when they decided they didn't want to close the doors.
If the lure from BioF did not change, then I'd guess the deal fell through because of the dilution beyond the shares reasonably available which would have been required.
Opinions expressed about managements salaries--stock issued in lieu of cash--hold no sway with me until the final results of their management moves and decisions have materialized.
Unfortunately, this is a penny stock. The chances of recovery should the final results be negative remain slim.
DNAP has performed remarkably, in my opinion--they're still here--, what with the storms and choppy seas thrown at them by market makers, maurading traders, and bashing employees of any and all who can't trust the market to act in their interest without coercing.
The proof of the latter resides more in the quick, incessant, and loudly proclaimed denials by the parties involved, than it does in my direct knowledge.
Finally, the environment for personalized medicine is here now, as we hoped it would have been four years ago. If DNAP has the technology they say they have, they should be as major a player there as they are in forensics and ancestry.
News 
Market Data 
Discover 
AI
